PharmaFocus Today – Page 30 – media

the legendary story of ketamine

1. Ketamine, once known as a “party drug,” is now reshaping the mental health field as a “miracle antidepressant.” Its core advantage lies in its rapid onset, relieving symptoms of severe depression within hours. This drug is particularly revolutionary for patients with treatment-resistant depression (TRD) who are resistant to traditional medications and those experiencing acute suicidal ideation. 2. Johnson & Johnson’s Spravato (esketamine nasal spray), a market pioneer, is expected to surpass $1.1 billion in sales in 2024, making it a blockbuster drug. However, its commercialization still faces three major challenges: strict regulation, high costs, and the risk of abuse. 3. In China, companies like Enhua Pharmaceutical and Hengrui Medicine are fiercely competing for the potentially safer and more effective R-ketamine. Beyond nasal sprays, companies around the world are also innovating in dosage forms like extended-release tablets. In clinical research, a team led by Dr. Wang Gang, President of Beijing ...
- Source: drugdu
- 149
- September 23, 2025
Clinical trial of combination therapy with new weight loss drug ASC47 achieves positive results

Ascletis Pharmaceuticals-B (01672) announced on the morning of September 22nd that its weight-loss without muscle-loss drug candidate, ASC47, combined with semaglutide, achieved positive results in a clinical trial in obese subjects. On day 29, the 30mg ASC47 plus semaglutide group demonstrated a 56.2% improvement in weight loss compared to semaglutide alone. The study, conducted in the United States, enrolled 28 obese subjects. Results showed that the combination of ASC47 and semaglutide significantly improved gastrointestinal tolerability compared to semaglutide alone, with a 6.7% incidence of vomiting in the combination group compared to 57.1% in the semaglutide alone group. Furthermore, the ultra-long-acting subcutaneous depot formulation of ASC47 resulted in less weight regain after discontinuation, supporting the potential use of once-monthly ASC47 as a maintenance therapy for weight loss. The study also showed that the 30mg and 60mg ASC47 groups significantly reduced low-density lipoprotein cholesterol compared to the semaglutide monotherapy group. ASC47 has ...
- Source: drugdu
- 134
- September 23, 2025
Huadong Medicine：Subsidiary ADC innovative drugClinical trial approved by the US FDA

On September 22, Huadong Medicine announced that its wholly-owned subsidiary, Zhongmei Huadong, received notification from the U.S. Food and Drug Administration (FDA) that Zhongmei Huadong’s clinical trial application for HDM2017 for injection has been approved by the FDA for Phase I clinical trials in the United States for the treatment of advanced malignant solid tumors. HDM2017 for injection is a novel antibody-drug conjugate (ADC) targeting cadherin 17 (LI-cadherin). Comment: The approval of the US clinical trial application for HDM2017 for injection marks another important step forward in the product’s development and will further enhance Huadong Medicine ‘s core competitiveness in oncology treatment. However, clinical trials inherently carry risks and uncertainties, and investors should carefully monitor subsequent results. https://finance.eastmoney.com/a/202509233520253862.html
- Source: drugdu
- 171
- September 23, 2025
The IND application for TQF3250 Capsules, a Class 1 innovative drug from China Biopharmaceuticals, with hypoglycemic activity comparable to similar drugs, has been accepted by the National Medical Products Administration (NMPA).

On September 22, China Biopharmaceutical (01177) announced that the company’s independently developed national Class 1 innovative drugThe new drug clinical trial application (IND) for TQF3250 capsules, a “GLP-1 receptor agonist”, has been accepted by the China National Medical Products Administration (NMPA) and is intended for the treatment of type 2 diabetes. TQF3250 is an oral, small-molecule, preferential GLP-1RA that selectively activates the cAMP-preferred GLP-1R signaling pathway, effectively promoting insulin secretion. Preclinical studies have shown that in mouse models, TQF3250 significantly improves glucose tolerance at doses as low as 1 mg/kg, demonstrating comparable activity to the similar drug orforglipron, demonstrating a highly effective hypoglycemic effect. Furthermore, TQF3250 has a no-adverse-effect-level (NOAEL) of 24 mg/kg/day, and no significant cardiotoxicity or genotoxicity risk has been observed, demonstrating a favorable safety profile. The global GLP-1RA market is projected to exceed US$50 billion in 2024 and exceed US$150 billion in 2031. The Company will accelerate ...
- Source: drugdu
- 123
- September 23, 2025
Eli Lilly invests $5 billion in U.S. plant to expand production of targeted cancer drugs and other therapies

On Tuesday, US Eastern Time, US pharmaceutical giant Eli LillyEli Lilly announced a $5 billion investment in a manufacturing facility in Goochland County, Virginia, to increase production of APIs and finished products for advanced therapies such as targeted cancer drugs. During U.S. trading, Eli Lilly’s stock price rose by over 2.5%. Eli Lilly stated that the new plant will be used to produce active ingredients for cancer and autoimmune disease drugs, as well as other advanced therapies. Eli Lilly emphasized that the plant will significantly enhance the local production capacity of antibody-drug conjugates (ADCs). ADCs are an emerging class of targeted therapies, often referred to as “biological missiles” in the industry. They combine monoclonal antibodies with toxic “payloads” to kill cancer cells. Currently, several pharmaceutical companies are developing or have already launched these drugs and are exploring their use in autoimmune diseases and other indications. “This is new capacity to ...
- Source: drugdu
- 123
- September 22, 2025
The investment logic of multinational pharmaceutical companies has changed

Recently, multiple sources have indicated that Bristol-Myers Squibb(BMS) will sell 60% of its stake in Shanghai Bristol-Myers Squibb Co., Ltd., and the buyer may be an affiliate of Hillhouse Capital Group. According to an email circulating online, BMS has signed an agreement to sell its 60% stake in Shanghai Bristol-Myers Squibb Pharmaceuticals Co., Ltd. and several related products manufactured and sold exclusively in mainland China to an affiliate of Hillhouse Capital. These products include Baraclude, Bufferin, Theragran, Monopril, and Velosef (Velosef). The transaction is expected to close in early 2026, and the specific amount was not disclosed. BMS stated that this divestiture will help it focus resources on core areas and optimize its business layout. BMS divests major assets According to data, in 1982, Shanghai Bristol-Myers Squibb was established by the American company Bristol-Myers Squibb and Shanghai Pharmaceuticals, the predecessor of Shanghai Pharmaceuticals Group.It was established as a joint venture ...
- Source: drugdu
- 139
- September 22, 2025
Changchun High-Tech invested nearly 1.5 billion yuan to introduce three new drugs

On September 17, Changchun High-Tech announced that its holding subsidiary Jinsai Pharmaceuticals had reached an allergen-specific immunotherapy (AIT) product cooperation with Denmark’s ALK-Abelló A/S (ALK). The company will jointly develop and commercialize ALK’s house dust mite (HDM) allergen-specific immunotherapy products in China, and obtain exclusive agency rights for three products independently developed by ALK in mainland China. According to the agreement, Jinsai Pharmaceutical will pay an initial payment of €32.7 million and a €40 million registration milestone payment for the dust mite allergen sublingual tablet (ACARIZAX) in China. Jinsai Pharmaceutical will also cover the majority of future Phase III bridging clinical study and registration costs for adult and adolescent indications, while both parties will each cover 50% of the clinical study and registration costs for pediatric indications. Furthermore, depending on the sales performance of these products in the Chinese market, Jinsai Pharmaceutical may make subsequent sales milestone payments of €105 ...
- Source: drugdu
- 138
- September 22, 2025
WALVAX’s clinical application for freeze-dried herpes zoster virus mRNA vaccine has been accepted

On September 19, WALVAX(300142) announced that its subsidiaries, Beijing Watson Innovation Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., and Yuxi WALVAXtechnology Co., Ltd., jointly developed with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd., have submitted their clinical trial application to the National Medical Products Administration and received a “Notice of Acceptance.” The vaccine’s primary function is to stimulate immunity against the herpes zoster virus and is intended for the prevention of shingles. The announcement mentioned that the acceptance numbers of the vaccine application are CXSL2500804 and CXSL2500805, and the registration classification is a preventive biological product.1.2. According to relevant regulations, after an application is accepted, it must undergo a technical review by the Center for Drug Evaluation of the National Medical Products Administration and obtain approval before clinical trials can begin. By mid-2025, WALVAX achieved revenue of 1.154 billion yuan and net profit attributable to shareholders of ...
- Source: drugdu
- 102
- September 22, 2025
New neuro-sensing technique captures brainwaves from within veins

Researchers at The University of Osaka have developed a groundbreaking, minimally invasive method for recording brain activity through blood vessels. This technique could potentially transform the diagnosis and treatment of neurological conditions like epilepsy and paving the way for advanced brain-computer interfaces. It eliminates the need for invasive open-brain surgery, offering a safer and more accessible way to monitor and stimulate brain function. Current methods for directly measuring brain activity require invasive procedures, either removing part of the skull to place electrodes on the brain surface or inserting electrodes directly into brain tissue. While non-invasive methods like EEG exist, they lack the precision needed for detailed analysis. This new method bridges the gap, offering high-fidelity recordings without the risks associated with traditional invasive approaches. The research team, led by Professor Takufumi Yanagisawa used a catheter to insert ultra-thin wire electrodes into the cortical and deep veins of pig brains. They ...
- Source: drugdu
- 119
- September 22, 2025
Why Mosquitos Might Be Attracted To You

By Deanna Neff HealthDay ReporterSATURDAY, Sept. 20, 2025 (HealthDay News) — Researchers in the Netherlands turned a major music festival into an unexpected laboratory to investigate a question that has long puzzled scientists and bug-bitten individuals alike: What makes some people more irresistible to mosquitoes than others? For three consecutive days at the Lowlands festival in Biddinghuizen, Netherlands, scientists set up a unique pop-up research site inside a series of shipping container laboratories. Instead of waiting for their favorite band, hundreds of festivalgoers lined up to volunteer for the “Mosquito Magnet Trial,” a study designed to measure their personal attractiveness to the insects. Inside the make-shift lab from 9 a.m. to 10 p.m. each day, groups of participants rested their arms against transparent acrylic boxes that had caged mosquitoes. As the insects responded to the human scent, a camera and computer system recorded mosquito movements and calculated a unique attraction ...
- Source: drugdu
- 84
- September 22, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.